Liraglutide Added to Standard Diabetes Therapy Improves Kidney Function, Reduces Fibrosis, and Boosts Immunity
Adding liraglutide to standard diabetes treatment improved kidney function (lower creatinine, BUN, and urinary protein), reduced renal fibrosis, and boosted immune markers in 42 T2DM patients compared to standard therapy alone.
Quick Facts
What This Study Found
Liraglutide + standard therapy achieved 97.6% effectiveness vs 78.6% for standard therapy alone, with significantly better blood glucose control, kidney function (Scr, BUN, 24h-UPor), renal fibrosis reduction, and immunoglobulin levels in 84 T2DM patients.
Key Numbers
84 patients total (42 per group). Study period: March 2021 to March 2022. Improvements in renal function, fibrosis markers, and immune parameters.
How They Did This
Retrospective analysis of 84 T2DM patients (42 per group) at First Affiliated Hospital of Jishou University (March 2021–March 2022). Control group received routine treatment; study group added liraglutide. Compared blood glucose, renal function, renal fibrosis markers, immunoglobulin levels, and adverse reactions.
Why This Research Matters
Diabetic kidney disease is the leading cause of kidney failure worldwide. Evidence that liraglutide not only controls blood sugar but also directly improves kidney function and reduces fibrosis supports its use as a kidney-protective therapy for diabetic patients.
The Bigger Picture
GLP-1 receptor agonists are increasingly recognized for kidney protection beyond blood sugar control. This adds to growing evidence that liraglutide may directly reduce kidney damage through anti-inflammatory and anti-fibrotic mechanisms, which could change how clinicians prioritize diabetes medications for patients at risk of kidney disease.
What This Study Doesn't Tell Us
Retrospective, non-randomized design at a single hospital with a small sample size (42 per group). The higher adverse reaction rate in the liraglutide group (19.1%) is notable and warrants attention. Short follow-up period. The study didn't control for all potential confounders.
Questions This Raises
- ?What specific adverse reactions occurred in the liraglutide group, and were any serious?
- ?Do the kidney benefits persist long-term, or are they only seen during active treatment?
- ?Would these kidney-protective effects be seen in patients with more advanced diabetic nephropathy?
Trust & Context
- Key Stat:
- 97.6% vs 78.6% Treatment effectiveness rate for liraglutide + standard therapy vs standard therapy alone in T2DM patients
- Evidence Grade:
- Moderate evidence from a small retrospective cohort study (84 patients). Results are suggestive but limited by the non-randomized design, single center, and small sample size.
- Study Age:
- Published in 2024 covering patients treated March 2021–March 2022.
- Original Title:
- Liraglutide combined with routine therapy improves renal function, renal fibrosis, immune status, and prognosis of type 2 diabetes patients.
- Published In:
- American journal of translational research, 16(7), 3405-3412 (2024)
- Authors:
- Xiong, Wen, Liu, Hongxia, Xiang, Bo, Shang, Guangyu
- Database ID:
- RPEP-09564
Evidence Hierarchy
Frequently Asked Questions
Can liraglutide protect kidneys in diabetic patients?
This study found that adding liraglutide to standard diabetes treatment significantly improved kidney function markers (creatinine, BUN, urinary protein) and reduced kidney fibrosis. Larger randomized trials have also shown kidney benefits for GLP-1 agonists, supporting their use in patients at risk for diabetic kidney disease.
Why did the liraglutide group have more side effects?
GLP-1 receptor agonists commonly cause gastrointestinal side effects like nausea, especially when first started. The 19.1% adverse reaction rate is within the expected range and these side effects typically diminish over time as the body adjusts.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09564APA
Xiong, Wen; Liu, Hongxia; Xiang, Bo; Shang, Guangyu. (2024). Liraglutide combined with routine therapy improves renal function, renal fibrosis, immune status, and prognosis of type 2 diabetes patients.. American journal of translational research, 16(7), 3405-3412. https://doi.org/10.62347/VYSW5854
MLA
Xiong, Wen, et al. "Liraglutide combined with routine therapy improves renal function, renal fibrosis, immune status, and prognosis of type 2 diabetes patients.." American journal of translational research, 2024. https://doi.org/10.62347/VYSW5854
RethinkPeptides
RethinkPeptides Research Database. "Liraglutide combined with routine therapy improves renal fun..." RPEP-09564. Retrieved from https://rethinkpeptides.com/research/xiong-2024-liraglutide-combined-with-routine
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.